The UK and US have concluded a important bilateral deal that will ensure no tariffs on British pharmaceutical exports entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to raise funding on drugs through the NHS. This move ensures that duties on these key goods will remain at nothing for a duration of the next three years.
This agreement comes after previous threats to hike tariffs on branded drug products, with increases floated up to 100%.
"This deal with the United Kingdom bolsters the global environment for cutting-edge drugs and introduces long-overdue equity to transatlantic drug exports," a statement said.
Trade Impact
Drugs represent one of the the United Kingdom's biggest goods shipped to the US, which is easily the largest market for large companies like GSK and AstraZeneca.
Trade data reveal that in the year to the end of September, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This amount accounted for nearly one-fifth of total UK exports in that timeframe.
"This deal safeguards work, increases funding and facilitates the UK to become a international leader for life sciences," the Business and Trade Secretary remarked.
Specific British Pledges
The pact involves several notable commitments from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to double total public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to control costs will be restricted at fifteen percent. In the past, rebates topped twenty percent.
Broader Context
The pact takes place against a long-running tension between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
This friction were heightened by arguments that US patients were charged significantly more for the identical medicines than consumers in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been halted or scrapped, while major expansions have been pledged toward US facilities.
A senior figure stated that the NHS must spend more on treatments, noting that its expenditure on drugs had declined as a proportion of its total funding over the previous ten-year period.
